Entyvio At-home Injection Approved in Europe to Treat Adults With IBD

Entyvio At-home Injection Approved in Europe to Treat Adults With IBD
The European Commission has approved a subcutaneous (under-the-skin) formulation of Entyvio (vedolizumab) for use as maintenance therapy in adults with moderately to severely active ulcerative colitis (UC) or Crohn’s disease (CD). This decision, which follows a positive recommendation from the Committee for Medicinal Products for Human Use, means that the formulation is now approved in the 27 member states of the European Union, as well as the United Kingdom, Norway, Liechtenstein, and Iceland. The medication will be made available in both a pre-filled syringe and a pre-filled pen. Entyvio, marketed by Takeda Pharmaceuticals, is an approved treatment for UC and CD that works by stopping inflammation-driving cells from getting into the gut. The therapy was previously available only by intravenous injection. The new subcutaneous formulation is more amenable to at-home treatment as it's generally easier to administer and requires less expertise to do so safely. “We are delighted that the European Commission has approved the subcutaneous formulation of Entyvio. This allows physicians and adult patients to choose the delivery method that works best for each individual patient,” Adam Zaeske, head of GI Franchise, Europe and Canada business unit, at Takeda, said in a press release. “Takeda’s commitment to treating gastrointestinal disease means that we are always looking to innovate to provide further therapeutic options to better meet the needs of the patients we serve.” The new approval was based on data from two Phase 3 trials — VISIBLE 1 (NCT02611830) in UC and VISIBLE 2 (NCT02611817) in CD — which evaluated the safety and efficacy of the subcutaneous formulation in participants with moderately to severely active disease. Collective
Subscribe or to access all post and page content.